A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics.
Development of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is to determine the likelihood of developing treatment-emergent anti-drug antibodies...
Guardado en:
Autores principales: | Joanne Lin, Stacey L Lee, Anna M Russell, Rong Fong Huang, Micheal A Batt, Shawn S Chang, Andrea Ferrante, Petra Verdino |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b3a2ef3195954b0488eb8607de448e39 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain
por: Derrick Johnson, et al.
Publicado: (2021) -
Potentials and limitations of microorganisms as renal failure biotherapeutics
por: Poonam Jain, et al.
Publicado: (2009) -
Gut microbiota: next frontier in understanding human health and development of biotherapeutics
por: Prakash S, et al.
Publicado: (2011) -
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
por: Natalia Ortega, et al.
Publicado: (2021) -
The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant
por: Delphine L. Lauté-Caly, et al.
Publicado: (2019)